Sensei Biotherapeutics To Present Topline Clinical Data From The SNS-101 Phase I Dose Escalation Study At The 2024 ASCO Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) announced it will present topline clinical data from its Phase 1/2 trial of SNS-101 at the 2024 ASCO Annual Meeting. SNS-101 is a conditionally active, human monoclonal antibody targeting VISTA, aimed at treating cancer. The data includes results from a study of SNS-101 alone or in combination with cemiplimab in patients with advanced solid tumors.
April 24, 2024 | 8:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sensei Biotherapeutics will present key data from its SNS-101 trial at the 2024 ASCO Meeting, potentially impacting its stock.
Presenting positive clinical trial data at a prestigious conference like ASCO can significantly boost investor confidence and potentially lead to an increase in stock price. Given the importance of SNS-101 in Sensei Biotherapeutics' pipeline and the focus on immuno-oncology, a field with high investor interest, the presentation could have a positive short-term impact on SNSE's stock price.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100